The Wall Street Journal: Catalent to buy Paragon Bioservices in $1.2 billion gene-therapy-drug deal

Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according to people familiar with the matter, the latest deal in the emerging market for gene-therapy drugs.